Figure 3.
Comparison of clinical efficacy between PAIA and IVIg. There were significant differences in ΔmRS1 (Z = -2.781, p = 0.005), ΔmRS2 (Z = -2.168, p = 0.03) and ΔCASE1 (t = -2.283, p = 0.027) after treatment (A–C), but ΔCASE2 (Z = -2.168, p = 0.943) showed no significant difference between the IVIg group and the PAIA group (D). mRS, modified Rankin scale; CASE, Clinical Assessment Scale for Autoimmune Encephalitis; IVIg, intravenous immunoglobulin; PAIA, protein A immunoadsorption. *P<0.05, ns, no significant.
